TherapeuticsMD (TXMD) Common Equity (2016 - 2025)
Historic Common Equity for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to $27.4 million.
- TherapeuticsMD's Common Equity rose 129.18% to $27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.4 million, marking a year-over-year increase of 129.18%. This contributed to the annual value of $27.4 million for FY2024, which is 654.56% down from last year.
- TherapeuticsMD's Common Equity amounted to $27.4 million in Q3 2025, which was up 129.18% from $27.3 million recorded in Q2 2025.
- Over the past 5 years, TherapeuticsMD's Common Equity peaked at $35.1 million during Q4 2022, and registered a low of -$140.6 million during Q1 2022.
- Moreover, its 5-year median value for Common Equity was $27.3 million (2025), whereas its average is -$4.0 million.
- Per our database at Business Quant, TherapeuticsMD's Common Equity plummeted by 138322.43% in 2022 and then soared by 21968.46% in 2023.
- Quarter analysis of 5 years shows TherapeuticsMD's Common Equity stood at -$93.6 million in 2021, then skyrocketed by 137.54% to $35.1 million in 2022, then fell by 16.66% to $29.3 million in 2023, then decreased by 6.55% to $27.4 million in 2024, then grew by 0.27% to $27.4 million in 2025.
- Its Common Equity was $27.4 million in Q3 2025, compared to $27.3 million in Q2 2025 and $26.7 million in Q1 2025.